Assessment of synthetic red cell therapy for extremely preterm ovine fetuses maintained on an artificial placenta life-support platform.

Haruo UsudaMasatoshi SaitoHideyuki IkedaShinichi SatoYusaku KumagaiYuya SaitoShinichi KawamuraTakushi HanitaHiromi SakaiShigeo KureNobuo YaegashiJohn P NewnhamMatthew W KempShimpei Watanabe

Published in: Artificial organs (2021)

Extremely preterm sheep fetuses were maintained for a period of up to 72 h using APT in combination with circuit priming using a synthetic red cell (HbV) preparation. Although significant further refinements are required, these findings demonstrated the potential clinical utility of synthetic blood products in the eventual clinical translation of artificial placenta technology to support extremely preterm infants.

Keyphrases

cell therapy
gestational age
low birth weight
preterm infants
preterm birth
stem cells
mesenchymal stem cells
hepatitis b virus
high throughput
single cell
risk assessment
molecularly imprinted